Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab

By Reuters News

Oct 1 (Reuters) - Almirall, S.A. ALM.MC:

  • PHASE 3B ADLONG CLINICAL STUDY SHOW TREATMENT OUTCOMES OVER TIME WITH UP TO FIVE YEARS OF LEBRIKIZUMAB TREATMENT IN MODERATE-TO-SEVERE ATOPIC DERMATITIS

  • SUSTAINED EFFICACY AND SAFETY DEMONSTRATED BY 92.9% OF PATIENTS ACHIEVING EASI-75 AND 73.8% ACHIEVING EASI-90 AT END OF STUDY

  • AT WEEK 108 OF CONTINUOUS TREATMENT, 66.7% OF PATIENTS ACHIEVED CLEAR OR ALMOST-CLEAR SKIN

  • AT WEEK 108 OF CONTINUOUS TREATMENT, 78.0% REPORTED ABSOLUTE PRURITUS SCORE OF FOUR OR LESS ON THE PRURITUS NUMERICAL RATING SCALE

Source text

Further company coverage: ALM.MC

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.